Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2022 Dec 30;17(12):e0279747. doi: 10.1371/journal.pone.0279747

Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study

Takuya Ogawa 1,2, Yuta Kajiyama 1, Hideaki Ishido 3,4, Shigeru Chiba 3,5, Gajanan S Revankar 1, Tomohito Nakano 6, Seira Taniguchi 1, Takashi Kanbayashi 3,5, Kensuke Ikenaka 1,*, Hideki Mochizuki 1,*
Editor: Claudio Liguori7
PMCID: PMC9803214  PMID: 36584130

Abstract

Patients with Parkinson’s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD. CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics. We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics. This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.

Introduction

Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are common neurodegenerative diseases associated with the accumulation of Lewy bodies; both cause motor symptoms, including resting tremor, rigidity, bradykinesia, and postural instability. PD also causes sleep disturbances, including insomnia, sleep attacks, excessive daytime sleepiness (EDS), and rapid eye movement sleep behavior disorder (RBD), which often impair patients’ cognition, psychiatric symptoms, and quality of life [1,2]. Sleep disturbances in patients with PD are not only due to the disease but also the treatment for PD, especially dopamine agonists (DAs) [3].

Orexin (also known as hypocretin) is a neuropeptide that regulates arousal and sleep. Deficiency of orexin neurons causes narcolepsy, characterized by EDS, sleep attacks, and cataplexy [4]. Narcolepsy-like symptoms are secondary to other neurological diseases, regardless of whether they occur owing to trauma, tumors, or immunological processes [4]. Since these sleep disturbances in PD are similar to those in narcolepsy, the association between orexin levels and PD has been studied [5]. Immunohistochemical analysis of the post-mortem brain tissues of patients with PD showed a decrease in orexin neurons, which further decreased with disease progression [6–8]. Moreover, the orexin levels in ventricular cerebrospinal fluid (CSF) also decrease in patients with advanced PD [7,9].

However, the implications of spinal CSF orexin levels in patients with PD remain inconclusive. In a study comparing orexin levels in patients with PD and controls, the orexin levels were lower in patients with PD than in controls [10], while others showed no significant difference [5,11]. A meta-analysis suggested that CSF orexin levels in patients with PD and DLB are lower than those in normal elderly individuals [12]. As the samples of those previous studies were small, studies with large samples are required to validate the difference in CSF orexin levels between PD and other conditions [13].

Regarding the clinical characteristics of PD, a previous study suggested that CSF orexin levels decrease with longer disease duration [14], while others showed no correlation [15]. EDS is one of the most common sleep disturbances in both PD and narcolepsy; however, studies focusing on EDS using the Epworth Sleepiness Scale (ESS) showed no significant correlation [16,17]. RBD is also seen in PD and narcolepsy, but the relationship between RBD and CSF orexin in PD is controversial. A study reported no significant differences between patients with PD with and without RBD [18], while the relationship between CSF orexin levels and the severity of RBD in patients with DLB has been demonstrated [19]. Furthermore, the effect of PD treatment using DAs on CSF orexin levels has been shown in vitro [20]; however, only one small study has suggested the effect in vivo [14].

Regarding the longitudinal disease progression, one study revealed that orexin levels decrease over years [21]. To our knowledge, no study has compared the changes in CSF orexin levels with disease progression in patients with PD. Thus, it is unknown whether CSF orexin levels can affect future clinical characteristics of PD.

Since previous studies had insufficient samples or used inconsistent methods of clinical assessment [10,11,13,14,16,18,19,21], the diagnostic or prognostic value of the CSF orexin level in PD lacks evidence. In this study, we measured orexin levels in the CSF samples obtained from patients with PD to clarify the role of orexin as a biomarker of PD, in the following particulars: (i) its difference between PD and other diseases, (ii) its association with the severity of sleep disturbances and other clinical characteristics, and (iii) its relationship with and predictive value of the longitudinal course of PD. This study may provide precise insights into sleep disturbance and an appropriate treatment target in PD.

Materials and methods

Participants

We selected two sets of participants from our previous cohort study [22,23]: (i) participants for longitudinal data and (ii) participants for extraction of cross-sectional data for analysis of the association between CSF orexin levels, sleep characteristics, and DA use in the treatment of PD (Fig 1). To obtain longitudinal data, all participants registered in our cohort study between April 2017 and August 2019 were recruited. The inclusion criteria were: (i) a confirmed diagnosis of PD according to the Movement Disorder Society Diagnostic Criteria for PD and (ii) evaluation of CSF at two or more different time periods. To obtain cross-sectional data, participants registered in our cohort study between April 2015 and April 2020 were recruited. The inclusion criteria were: (i) both confirmatory and probable diagnoses of PD, (ii) disease duration within eight years of motor onset, and (iii) medication with a single DA use or without DAs. Participants taking orexin receptor antagonists were excluded from both data sets. All those without adequate clinical evaluation results with the ESS [24] and Rapid Eye Movement Sleep Behavior Disorder Questionnaire (RBDQ) [25] were also excluded from the comparison of clinical characteristics among PD patients. Age- and sex-matched controls were selected from patients without neurodegenerative diseases.

Fig 1. Flowchart illustrating the study design.

Fig 1

Open in a new tab

Confirmatory or probable PD were diagnosed according to the Movement Disorder Society Diagnostic Criteria for PD. N, number of samples; PD, Parkinson’s disease; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; DA, dopamine agonist.

Patients with PD were categorized according to three criteria: (i) the EDS- group with ESS scores <11 and the EDS+ group with ESS scores ≥11 according to the original report [24]; (ii) the RBD- group with RBDQ scores <5 and RBD+ group with RBDQ scores ≥5 according to the original report [25]; and (iii) the RTG group with patients on rotigotine, ROP group with patients on ropinirole, PPX group with patients on pramipexole, and no DA group with patients who were never on DAs.

Longitudinal changes were calculated from the clinical and CSF data of patients with PD obtained during different periods. In patients with PD examined more than three times, longitudinal changes were calculated from each dataset using the initial data.

Ethics

This study was conducted as part of a prospective and exploratory study for disease-specific biomarkers and objective indicators in neurodegenerative diseases (UMIN-CTR: UMIN000036570) and the Osaka University Longitudinal Biomarker Study for Neuromuscular Diseases. This study was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects endorsed by the Japanese government. The Ethics Committee of Osaka University Graduate School of Medicine approved this study (approval numbers: 13471 and 19089). All patients, including the controls, were informed about this study and provided written consent.

Clinical assessment

To evaluate the association between CSF orexin levels and sleep disturbances, we obtained clinical characteristics, including age, sex, disease duration, and levodopa equivalent daily dose of anti-Parkinson drugs. Sleep disturbance was assessed using the ESS and RBDQ. To assess the general clinical features of PD, we obtained the Hoehn and Yahr scale (HYscale) [26], Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [27], and Parkinson’s Disease Questionnaire (PDQ-39) results [28]. Cognitive dysfunction was assessed using the Mini-Mental State Examination (MMSE) [29] and frontal assessment battery (FAB) [30]. To assess the non-motor symptoms of PD, we obtained the olfactory identification score, Scales for Outcomes in Parkinson’s Disease-Autonomic (SCOPA-AUT) [31], Geriatric Depression Scale (GDS-15) [32], and Apathy Scale (AS) [33]. The olfactory identification score was measured using a card-type kit (“Open Essence”; FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan).

Orexin measurements

CSF was collected by lumbar puncture in the morning after overnight fasting, keeping the usual medications. The CSF samples were centrifuged at 400 × g for 10 min at 4°C, and aliquots were stored at −80°C before analysis. CSF orexin levels were measured using a radioimmunoassay kit (Phoenix Pharmaceuticals, Belmont, CA, USA) by the International Institute for Integrative Sleep Medicine at the University of Tsukuba.

Statistical analysis

Python version 3.7.6 was used to perform all statistical analyses. The orexin levels and clinical characteristics between the groups were compared using the Mann–Whitney U test, except for sex, using the chi-square test. Correlations between orexin and age, disease duration, HYscale, MDS-UPDRS, PDQ-39, MMSE, FAB, ESS, RBDQ, olfactory identification score, SCOPA-AUT, GDS-15, and AS were evaluated using Spearman’s rank correlation coefficient. Longitudinal changes in orexin levels were evaluated using the Wilcoxon signed-rank test. The effect size was calculated by dividing Z statistics by the square root of the sample size. Statistical significance was set at 0.05, with Bonferroni correction, if necessary.

Based on previous studies, we considered age, sex, disease duration, sleep disturbance, severity of PD, and cognitive function as confounding factors. Therefore, multivariable analysis was conducted using a linear regression model with CSF orexin levels as a dependent variable, and clinical characteristics including age, sex, disease duration, ESS, MDS-UPDRS part 3, and MMSE as independent variables. Before analysis, all clinical characteristics were standardized. Participants with missing data for any of these clinical characteristics were excluded before correlation analysis and multiple linear regression analysis.

Results

Clinical characteristics of participants

The clinical characteristics of the study participants are shown in Table 1. A total of 78 CSF samples from 58 patients with PD were analyzed in this study, including 16 patients with two longitudinal samples and two patients with three samples taken at different time periods. The control group consisted of 16 patients with idiopathic normal pressure hydrocephalus, two patients with cervical spondylotic myelopathy, one patient with psychosomatic disease, one patient with complex regional pain syndrome, and one patient without neurological or psychological disease. The clinical characteristics of each group are presented in Table 1.

Table 1. Characteristics of participants*.

PD Control EDS+ EDS- RBD+ RBD- RTG ROP PPX no DA
N N N N N N N N N N
N(p) 58 20 21 32 20 33 9 6 8 34
N(s) 78 21 25 43 24 44 11 7 8 40
Sex ** 42: 36 12: 9 14: 11 23: 20 15: 9 22: 22 4: 7 4: 3 3: 5 24: 16
Age 78 69.0 [62.2–74.0] 21 72.0 [68.0–75.0] 25 67.0 [64.0–73.0] 43 69.0 [61.0–74.0] 24 67.0 [64.8–74.0] 44 69.0 [61.0–72.2] 11 71.0 [63.0–73.5] 7 63.0 [57.0–69.5] 8 67.5 [64.0–71.0] 40 69.0 [61.0–74.0]
Duration 78 5.0 [3.0–7.0] NA 25 5.0 [4.0–7.0] 43 4.0 [2.0–6.0] 24 6.0 [4.8–8.0] 44 4.0 [2.0–6.0] *c 11 6.0 [4.5–7.5] 7 5.0 [4.0–7.0] 8 5.5 [4.8–6.2] 40 4.0 [2.0–5.2]
ESS 68 8.0 [5.0–13.0] NA 25 16.0 [13.0–18.0] *b 43 5.0 [3.0–8.0] 24 13.5 [8.8–18.5] 44 6.5 [3.8–10.0] *c 11 13.0 [9.0–18.5] *d 7 10.0 [9.5–12.0] 8 8.0 [6.5–11.0] 40 6.0 [3.0–10.0]
RBDQ 69 3.0 [1.0–5.0] NA 25 5.0 [3.0–8.0] *b 43 2.0 [1.0–4.0] 24 6.0 [5.0–8.2] 44 1.0 [1.0–3.0] *c 11 5.0 [4.5–6.5] 7 1.0 [0.5–2.5] 8 4.0 [1.0–5.0] 40 2.0 [1.0–4.2]
HYscale 77 2.0 [2.0–3.0] NA 25 2.0 [2.0–3.0] 43 2.0 [2.0–3.0] 24 2.0 [2.0–3.0] 44 2.0 [2.0–3.0] 11 3.0 [2.0–3.0] 7 3.0 [2.0–4.0] 8 2.0 [2.0–2.2] 40 2.0 [2.0–3.0]
UPDRS (I) 74 9.5 [5.0–14.0] NA 25 12.0 [9.0–18.0] *b 42 8.0 [3.0–12.8] 24 14.0 [11.0–19.0] 43 8.0 [3.0–11.0] 11 18.0 [13.0–20.5] *d 7 11.0 [8.0–13.0] 8 8.5 [5.8–9.5] 39 8.0 [3.5–12.0]
UPDRS (II) 74 12.0 [7.0–18.0] NA 25 16.0 [13.0–18.0] *b 42 9.0 [6.0–17.5] 24 18.0 [15.0–23.5] 43 8.0 [5.0–15.5] 11 18.0 [15.5–24.0] *d 7 15.0 [10.5–20.0] 8 11.0 [5.2–12.0] 39 9.0 [5.5–17.0]
UPDRS (III) 76 26.5 [19.0–37.5] NA 25 28.0 [22.0–34.0] 43 26.0 [16.0–40.0] 24 33.0 [22.0–41.5] 44 23.0 [13.0–32.8] 11 31.0 [20.0–37.0] 7 27.0 [24.0–41.0] 8 20.0 [12.5–21.5] 40 28.0 [18.8–37.5]
UPDRS (IV) 74 0.0 [0.0–5.8] NA 25 2.0 [0.0–7.0] *b 42 0.0 [0.0–4.8] 24 5.5 [0.0–8.0] 43 0.0 [0.0–2.5] 11 8.0 [2.5–8.5] *d 7 2.0 [1.5–6.0] 8 0.0 [0.0–1.2] 39 0.0 [0.0–3.5]
PDQ-39 68 32.5 [22.8–61.0] NA 25 61.0 [45.0–76.0] *b 42 25.5 [15.5–33.8] 24 61.0 [47.2–77.5] 43 27.0 [16.0–33.5] 11 59.0 [51.0–75.0] *d 7 30.0 [29.0–58.0] 8 37.0 [27.8–47.8] 39 27.0 [16.0–59.5]
MMSE 77 27.0 [25.0–30.0] NA 25 27.0 [22.0–29.0] 43 28.0 [26.0–30.0] 24 26.0 [22.8–29.0] 44 29.0 [26.0–30.0] 11 26.0 [23.0–29.0] 7 30.0 [27.5–30.0] 8 27.0 [26.0–30.0] 40 28.0 [26.0–30.0]
FAB 76 15.0 [13.0–17.0] NA 25 15.0 [12.0–17.0] 43 15.0 [13.0–17.0] 24 14.5 [11.8–16.0] 44 15.0 [13.0–18.0] 11 14.0 [12.0–14.5] 7 16.0 [14.0–17.5] 8 15.0 [13.8–16.2] 40 15.0 [13.8–18.0]
Olfactory 74 3.5 [2.0–5.0] NA 24 3.0 [2.0–5.0] 42 4.0 [3.0–5.0] 23 3.0 [1.5–4.0] 43 4.0 [3.0–5.5] 10 2.5 [2.0–4.8] 7 3.0 [3.0–3.5] 8 4.5 [3.0–6.2] 39 4.0 [3.0–5.0]
SCOPA-AUT 70 14.5 [8.0–22.0] NA 25 18.0 [13.0–27.0] *b 43 12.0 [6.0–19.0] 24 22.0 [16.8–28.2] 44 12.0 [6.0–16.2] 11 14.0 [9.5–24.5] 7 16.0 [13.5–21.5] 8 21.5 [15.2–24.2] 40 12.5 [6.0–18.0]
GDS-15 69 4.0 [2.0–7.0] NA 25 6.0 [4.0–10.0] *b 43 3.0 [2.0–5.0] 24 6.0 [3.8–8.2] 44 3.0 [2.0–5.2] 11 7.0 [2.0–9.0] 7 4.0 [2.0–7.0] 8 4.0 [2.2–5.0] 40 4.0 [2.0–6.0]
AS 69 14.0 [8.0–18.0] NA 25 15.0 [9.0–23.0] 43 14.0 [7.0–17.0] 24 14.0 [8.8–22.0] 44 14.0 [7.0–17.0] 11 13.0 [8.5–17.5] 7 14.0 [9.5–24.0] 8 14.0 [10.0–15.0] 40 15.0 [7.0–18.2]
Orexin 78 272.0 [221.7–334.5] *a 21 352.2 [296.2–399.5] 25 278.7 [235.3–329.2] 43 260.4 [203.6–309.7] 24 263.0 [227.8–306.3] 44 271.1 [217.0–336.3] 11 275.2 [236.3–338.5] 7 271.8 [257.9–322.2] 8 231.7 [207.7–278.8] 40 269.8 [204.6–318.6]
Open in a new tab

PD, Parkinson’s disease; EDS, excessive daytime sleepiness; RBD, rem eye movement sleep behavior disorder; RTG, rotigotine; ROP, ropinirole; PPX, pramipexole; no DA, no use of dopamine agonist; N(p), number of patients; N(s), number of samples; HYscale, Hoehn and Yahr scale; UPDRS(I)—(IV), Movement Disorder Society—Unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale; NA, no data available.

*median [lower–upper bound of interquartile range].

**number of men: Women.

a Significant differences (p < 0.05) were found between the PD and control groups with the Mann–Whitney U test.

b Significant differences (p < 0.05) were found between the EDS+ and EDS- groups with the Mann–Whitney U test.

c Significant differences (p < 0.05) were found between the RBD+ and RBD- groups with the Mann–Whitney U test.

d Significant differences (p < 0.05) were found between the RTG and no DA groups with the Mann–Whitney U test.

Orexin levels of patients with Parkinson’s disease

First, we examined CSF orexin levels in patients with PD and controls (Fig 2 and Table 1). The median CSF orexin level of patients with PD (272.0 [interquartile range (IQR) = 221.7–334.5] pg/mL) was significantly lower than that of controls (352.2 [296.2–399.5] pg/mL) (Z statistic = 2.72, p = 0.007, effect size r = 0.270).

Fig 2. Boxplot of CSF orexin levels.

Fig 2

Open in a new tab

Boxplots showing the comparison between (A) the PD and control group, (B) EDS+ and EDS- group, (C) RBD+ and RBD- group, and (D) RTG, ROP, PPX and no DA groups. PD, Parkinson’s disease; EDS, excessive daytime sleepiness; RBD, rapid eye movement sleep behavior disorder; RTG, rotigotine; ROP, ropinirole; PPX, pramipexole; no DA, no use of dopamine agonist; CSF, cerebrospinal fluid. * Significant differences were observed between the PD and control groups.

Orexin levels and clinical characteristics

We analyzed 68 CSF samples of patients with PD with adequate data by group comparisons. When groups were compared, no significant differences were noted in CSF orexin levels between the EDS+ (278.7, IQR = [235.3–329.2] pg/mL) and EDS- (260.4 [203.6–309.7] pg/mL) groups, and the RBD+ (263.0 [227.8–306.3] pg/mL) and RBD- (271.1 [217.0–336.3] pg/mL) groups. Moreover, the RTG (275.2 [236.3–338.5] pg/mL), ROP (271.8 [257.9–322.2] pg/mL), and PPX (231.7 [207.7–278.8] pg/mL) groups also showed no difference when compared with the noDA (269.8 [204.6–318.6] pg/mL) group (Fig 2 and Table 1).

The correlations between CSF orexin levels and sleep disturbances were also assessed. The correlation coefficients (ρ) between orexin and disease duration, ESS, and RBDQ were 0.198 (95% confidence interval (95%CI) = [-0.04–0.42], p = 0.11), 0.021 ([-0.22–0.26], p = 0.87) and 0.079 ([-0.16–0.31], p = 0.52), respectively (Fig 3). There were no statistically significant correlations between CSF orexin levels and other clinical characteristics (S1 Table).

Fig 3. Correlation between orexin levels and clinical characteristics in patients with Parkinson’s disease.

Fig 3

Open in a new tab

In each scatter plot, the x-axis shows CSF orexin levels and the y-axis shows (A) disease duration, (B) ESS, and (C) RBDQ. The disease duration was scaled by year. All these clinical characteristics showed poor correlation with CSF orexin levels, and the correlation coefficients were not statistically significant. CSF, cerebrospinal fluid; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire.

Multiple linear regression showed no significant correlation between orexin levels and other clinical characteristics, including age, sex, disease duration, ESS, MDS-UPDRS part 3, and MMSE, with an adjusted R2 of 0.078 (degrees of freedom = 6, F statistic = 1.94, p = 0.09). Regression coefficients (β) of clinical characteristics were 9.74 for age (95%CI = [-12.75–32.23], t statistic = 0.87, p = 0.39), -7.69 for sex ([-29.8–14.42], t = -0.7, p = 0.49), 22.36 for disease duration ([0.52–44.19], t = 2.05, p = 0.04), 1.02 for ESS ([-19.94–21.99], t = 0.1, p = 0.92), -21.49 for UPDRS (III) ([-43.63–0.64], t = -1.94, p = 0.06), and -15.56 for MMSE ([-40.39–9.26], t = -1.25, p = 0.22).

Orexin levels in clinical course of patients with Parkinson’s disease

We analyzed 16 time-series sets of samples from 15 patients. One patient had two sets. Longitudinal changes in CSF orexin levels are shown in Fig 4. Among these 16 sets, 12 showed an increase in CSF orexin levels from initial examinations. The median of this increase in CSF orexin levels from baseline (38.1 pg/mL) was not statistically significant (95%CI = [-32.9–95.2], Z statistic = -1.84, p = 0.07, effect size r = -0.325).

Fig 4. Longitudinal changes in orexin levels in Parkinson’s disease.

Fig 4

Open in a new tab

In this scatter plot, the x-axis shows the time period since the initial measurement and the y-axis shows CSF orexin levels. Blue triangles show 12 cases with increased CSF orexin levels after the interval, and red inverted triangles show 4 cases with decreased CSF orexin levels after the interval.

There were no correlations between the longitudinal changes in CSF orexin levels and those of ESS (ρ = 0.13, 95% CI = [-0.39–0.59], p = 0.63) or RBD (ρ = 0.09 [-0.43–0.56], p = 0.74) (Fig 5); there were also no correlations between CSF orexin changes and other clinical characteristics. (S2 Table). No obvious relationship was found between initial CSF orexin levels and longitudinal changes in ESS (ρ = 0.17 [-0.35–0.61], p = 0.53) and RBD (ρ = -0.04 [-0.53–0.46], p = 0.88) (Fig 6).

Fig 5. Scatter plot of longitudinal changes in orexin levels and main clinical characteristics.

Fig 5

Open in a new tab

The x-axis shows the increase in CSF orexin levels since the initial examination, and the y-axis shows the increase in (A) ESS or (B) RBDQ since the initial examination. There was no correlation between the increase in CSF orexin levels and the clinical scores. Δ-, increment of -; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Behavior Disorder Questionnaire.

Fig 6. Scatter plot of initial cerebrospinal fluid orexin levels and longitudinal changes in main clinical characteristics.

Fig 6

Open in a new tab

The x-axis shows the initial CSF orexin levels, and the y-axis shows the increase in (A) ESS or (B) RBDQ from the initial examination. There was no correlation between the initial CSF orexin levels and the increase in clinical scores. Δ-, increment of -; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Behavior Disorder Questionnaire.

Discussion

To our knowledge, this is the study with the largest number of CSF samples of patients with PD. Here, we investigated the role of orexin in PD compared to controls, the relationship between orexin and various clinical characteristics, and the effect of orexin on longitudinal changes in PD. We revealed decreased CSF orexin levels in patients with PD, which were poorly related to any cross-sectional and longitudinal clinical characteristics in PD.

Orexin in PD compared to controls

Our study showed that CSF orexin levels in patients with PD were lower than those in the controls. However, the pathological relevance of CSF orexin level needs to be considered. The normal range for CSF orexin level defined for the diagnosis of narcolepsy is as follows: over 200 pg/mL is normal, between 110 and 200 pg/mL in intermediate, and under 110 pg/mL is the abnormal [34]. In our study, the median CSF orexin level was within the normal range, and 64 out of 78 CSF samples (82.1%) showed a normal orexin range (over 200 pg/mL). Although one study showed that CSF orexin levels in patients with PD decreased to an intermediate range [13], other studies demonstrated normal CSF orexin levels in these patients [11,12]. In our study, CSF orexin levels in patients with PD were lower than those of controls, but this reduction was smaller than that in patients with narcolepsy.

Correlation of orexin with clinical characteristics

First, our study showed that there was no significant difference in CSF orexin levels in the presence and absence of EDS. Second, no difference was noted in these levels between patients with and those without RBD. We did not observe a relationship between the severity of sleep disturbances and orexin levels using simple regression or multiple linear regression analysis. This study emphasizes the minute effect of orexin on EDS and its negative impact on RBD. The other clinical characteristics were not correlated. Previous studies on this correlation had conflicting outcomes; some reported no correlation between CSF orexin levels and ESS [12,14], but multiple sleep latency tests showed a positive correlation between CSF orexin levels and shortened sleep latency [21]. For the RBDQ, some studies showed a relationship with CSF orexin levels [19], but others did not [13].

In our study, the difference observed in CSF orexin levels between patients with PD and those with narcolepsy might be due to the pathological characteristics of these diseases. Pathological analysis showed that α-synuclein deposits that were seen in patients with PD were not found in those with narcolepsy, which might have caused a different trend in video-polysomnography analysis for RBD in PD and narcolepsy [35]. Neuronal loss in narcolepsy is limited to orexin neurons, but PD is a neurodegenerative disease, where broad neuronal systems are impaired, including not only orexin neurons, but also noradrenaline, serotonin, and acetylcholine neurons. These neurotransmitters also play important roles in sleep-arousal mechanisms [36]. Furthermore, orexin fibers project widely to the nuclei in the brainstem and hypothalamus, including the locus coeruleus and raphe nuclei [37]. These nuclei are damaged in PD [38], which may cause dysfunction of the orexin system without damaging orexin neurons through a decrease in orexin receptors. Therefore, CSF orexin levels are poorly correlated to clinical sleep disturbances in PD.

Our study showed no significant differences in CSF orexin levels between patients with PD with and those without DAs. Since our study was retrospective, it is possible that DA had already been discontinued owing to adverse effects. A previous study showed an improvement in EDS and an increase in CSF orexin levels after switching from PPX to pergolide [14]. In clinical situations, the effect of DA use on orexin levels seems to be small, but further studies are needed to focus on cases with adverse sleep events.

Taking all the results together, we believe that the decreased orexin level in patients with PD does not exert a substantial effect on the PD pathologies, at least at the relatively early stage that we have examined.

Effect of orexin on longitudinal changes in PD

Our study showed no significant correlation between CSF orexin levels and PD disease duration, which is in line with a previous study [15]; however, another study demonstrated a negative correlation between CSF orexin levels and disease duration [14]. This discrepancy in results could be due to differences in study conditions such as patient numbers.

This study focused on the relationship between longitudinal changes in CSF orexin levels and clinical characteristics. Our study revealed that the CSF orexin level was a poor predictor of the clinical course, including sleep disturbances in PD. A previous study in rats revealed that 73% of orexin neurons are lost when CSF orexin levels from the cisterna magna are reduced to half, and CSF orexin levels are not related to the decline in orexin neurons [39]. According to a previous report, patients with advanced PD (HYscale score = 4) still have more than half the number of orexin cells compared to those in healthy controls [7]; therefore, the decrease in orexin neurons may not appear in the CSF until the advanced stage of PD. In our study, the intervals from the initial examinations were no more than three years, which may be too short to observe the progression of PD and changes in the orexin system.

Limitations

Our study had several limitations. First, it was retrospective in nature, which might have caused selection bias. Second, EDS and RBD were evaluated only by a subjective questionnaire, so they may not reflect the objective sleep period and rhythms. Third, we included only a few patients with advanced PD, and the intervals from the initial examinations were within three years. The absence of long-term data has led to biased analysis. Fourth, we recruited patients who were not diagnosed with neurodegenerative diseases, including those with normal pressure hydrocephalus, as controls. These patients potentially differ from the healthy elderly; however, patients with these diseases were assigned to control groups in a previous study [40] and were shown to have normal orexin levels [41]. Fifth, all patients had optimal medication during examinations; therefore, we could not rule out the impact of dopamine replacement therapy. Since DAs, including levodopa, affect circadian regulation, we could not eliminate such effects from the drugs [2].

Conclusion

Although orexin is important for normal sleep regulation, our results emphasized that the efficacy of CSF orexin levels as a biomarker for PD is limited. Since many nervous systems are impaired in PD, the relationship with other neurotransmitters should also be evaluated. To determine the impact of orexin levels on PD, it may be necessary to further evaluate drug-naive patients or advanced patients with significant orexin neuronal loss. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance, which may contribute to improving the quality of life of patients with PD.

Supporting information

S1 Table. Correlation between cerebrospinal fluid orexin levels and clinical characteristics in Parkinson’s disease.

The table shows Spearman’s rank correlation coefficients for orexin levels and clinical characteristics. No clinical characteristics showed a significant correlation with CSF orexin levels. 95%CI, 95% confidence interval; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HYscale, Hoehn and Yahr scale; MDS-UPDRS(I)—(IV), Movement Disorder Society—Unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale.

(XLSX)

Click here for additional data file. (9.7KB, xlsx)
S2 Table. Correlation between longitudinal changes orexin levels and clinical characteristics in Parkinson’s disease.

The table shows the Spearman’s rank correlation coefficients for longitudinal changes in orexin levels and clinical characteristics. There were no significant correlations between longitudinal changes in orexin levels and clinical characteristics. 95%CI, 95% confidence interval; Δ-, increment of -; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HYscale, Hoehn and Yahr scale; MDS-UPDRS(I)—(IV), Movement Disorder Society—unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale.

(XLSX)

Click here for additional data file. (9.8KB, xlsx)
S3 Table. Correlation between initial cerebrospinal fluid orexin levels and longitudinal changes in clinical characteristics in Parkinson’s disease.

The table shows Spearman’s rank correlation coefficients for initial orexin levels and longitudinal changes in clinical characteristics. There was no significant correlation between initial CSF orexin levels and longitudinal changes in clinical characteristics. 95%CI, 95% confidence interval; Δ-, increment of -; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HYscale, Hoehn and Yahr scale; MDS-UPDRS(I)—(IV), Movement Disorder Society—unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale.

(XLSX)

Click here for additional data file. (10.7KB, xlsx)

Data Availability

All data files are available from the Dryad database (DOI: 10.5061/dryad.905qfttq0).

Funding Statement

YK and HM reports grants (Grant number 20FC1049) from the Research Committee of Central Nervous System Degenerative Diseases, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health, Labour and Welfare Sciences Research Grants, the Ministry of Health, Labour and Welfare, Japan (https://www.mhlw.go.jp/english/); the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. TK reports grants (Grant number JP19dm0908001, JP20dm0107162, JP21zf0127005) from AMED (https://www.amed.go.jp/), and grants (19K08037) from JSPS KAKENHI Grant-in-Aid for Scientific Research (https://www.jsps.go.jp/j-grantsinaid/); the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2017;19: 26. doi: 10.1007/s11940-017-0461-6 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Videnovic A, Lazar AS, Barker RA, Overeem S. ‘The clocks that time us’—circadian rhythms in neurodegenerative disorders. Nat Rev Neurol. 2014;10: 683–693. doi: 10.1038/nrneurol.2014.206 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Stevens S, Cormella CL, Stepanski EJ. Daytime sleepiness and alertness in patients with Parkinson disease. Sleep. 2004;27: 967–972. doi: 10.1093/sleep/27.5.967 . [DOI] [PubMed] [Google Scholar]
  • 4.Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9: 269–310. doi: 10.1016/j.smrv.2005.03.004 . [DOI] [PubMed] [Google Scholar]
  • 5.Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ. Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology. 2002;58: 498–499. doi: 10.1212/wnl.58.3.498 . [DOI] [PubMed] [Google Scholar]
  • 6.Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss in Parkinson’s disease. Brain. 2007;130: 1577–1585. doi: 10.1093/brain/awm090 . [DOI] [PubMed] [Google Scholar]
  • 7.Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130: 1586–1595. doi: 10.1093/brain/awm097 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, et al. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. NeuroReport. 2010;21: 756–760. doi: 10.1097/WNR.0b013e32833bfb7c . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Créange A, Remy P, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology. 2003;61: 540–543. doi: 10.1212/01.wnl.0000078194.53210.48 . [DOI] [PubMed] [Google Scholar]
  • 10.Wennström M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis. 2012;29: 125–132. doi: 10.3233/JAD-2012-111655 . [DOI] [PubMed] [Google Scholar]
  • 11.Trotti LM, Bliwise DL, Keating GL, Rye DB, Hu WT. Cerebrospinal fluid hypocretin and nightmares in dementia syndromes. Dement Geriatr Cogn Dis Extra. 2021;11: 19–25. doi: 10.1159/000509585 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gan J, Chen Z, Han J, Ma L, Liu S, Wang XD, et al. Orexin-A in patients With lewy body disease: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12: 765701. doi: 10.3389/fendo.2021.765701 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yuan Y, Zhang Y, Cheng Y, Hou Y, Huang Z, Ma J, et al. Cerebrospinal fluid TNF-α and orexin in patients With Parkinson’s disease and rapid eye movement sleep behavior disorder. Front Neurol. 2022;13: 826013. doi: 10.3389/fneur.2022.826013 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin Neurol Neurosurg. 2009;111: 341–344. doi: 10.1016/j.clineuro.2008.11.007 . [DOI] [PubMed] [Google Scholar]
  • 15.Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2006;250: 120–123. doi: 10.1016/j.jns.2006.08.004 . [DOI] [PubMed] [Google Scholar]
  • 16.Compta Y, Santamaria J, Ratti L, Tolosa E, Iranzo A, Muñoz E, et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson’s disease dementia. Brain. 2009;132: 3308–3317. doi: 10.1093/brain/awp263 . [DOI] [PubMed] [Google Scholar]
  • 17.Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur Neurol. 2004;52: 73–76. doi: 10.1159/000079749 . [DOI] [PubMed] [Google Scholar]
  • 18.Anderson KN, Vincent A, Smith IE, Shneerson JM. Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder. Eur J Neurol. 2010;17: 1105–1107. doi: 10.1111/j.1468-1331.2010.02954.x . [DOI] [PubMed] [Google Scholar]
  • 19.Inagawa Y, Shimizu S, Takenoshita N, Tsugawa A, Hirose D, Kanbayashi T, et al. Association between cerebrospinal fluid orexin A level and severity of rapid eye movement sleep behaviour disorder in dementia with Lewy bodies. Psychogeriatrics. 2021;21: 128–130. doi: 10.1111/psyg.12618 . [DOI] [PubMed] [Google Scholar]
  • 20.Michinaga S, Hisatsune A, Isohama Y, Katsuki H. An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture. Neurosci Res. 2010;68: 315–321. doi: 10.1016/j.neures.2010.08.005 . [DOI] [PubMed] [Google Scholar]
  • 21.Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M, et al. Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness? J Sleep Res. 2012;21: 710–717. doi: 10.1111/j.1365-2869.2012.01027.x . [DOI] [PubMed] [Google Scholar]
  • 22.Nakano T, Kajiyama Y, Revankar GS, Hashimoto R, Watanabe Y, Kishima H, et al. Neural networks associated with quality of life in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2021;89: 6–12. doi: 10.1016/j.parkreldis.2021.06.007 . [DOI] [PubMed] [Google Scholar]
  • 23.Kajiyama Y, Hattori N, Nakano T, Revankar GS, Otomune H, Hashimoto R, et al. Decreased frontotemporal connectivity in patients with Parkinson’s disease experiencing face pareidolia. npj Parkinsons Dis. 2021;7: 90. doi: 10.1038/s41531-021-00237-z . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14: 540–545. doi: 10.1093/sleep/14.6.540 . [DOI] [PubMed] [Google Scholar]
  • 25.Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord. 2007;22: 2386–2393. doi: 10.1002/mds.21740 . [DOI] [PubMed] [Google Scholar]
  • 26.Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17: 427–442. doi: 10.1212/wnl.17.5.427 . [DOI] [PubMed] [Google Scholar]
  • 27.Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23: 2129–2170. doi: 10.1002/mds.22340 . [DOI] [PubMed] [Google Scholar]
  • 28.Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26: 2371–2380. doi: 10.1002/mds.23834 . [DOI] [PubMed] [Google Scholar]
  • 29.Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: 189–198. doi: 10.1016/0022-3956(75)90026-6 . [DOI] [PubMed] [Google Scholar]
  • 30.Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55: 1621–1626. doi: 10.1212/wnl.55.11.1621 . [DOI] [PubMed] [Google Scholar]
  • 31.Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord. 2004;19: 1306–1312. doi: 10.1002/mds.20153 . [DOI] [PubMed] [Google Scholar]
  • 32.Yesavage JA, Sheikh JI. 9/Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5: 165–173. doi: 10.1300/J018v05n01_09 [DOI] [Google Scholar]
  • 33.Starkstein SE, Fedoroff JP, Price TR, Leiguarda R, Robinson RG. Apathy following cerebrovascular lesions. Stroke. 1993;24: 1625–1630. doi: 10.1161/01.str.24.11.1625 [DOI] [PubMed] [Google Scholar]
  • 34.Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59: 1553–1562. doi: 10.1001/archneur.59.10.1553 . [DOI] [PubMed] [Google Scholar]
  • 35.Antelmi E, Pizza F, Donadio V, Filardi M, Sosero YL, Incensi A, et al. Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients. Ann Clin Transl Neurol. 2019;6: 1872–1876. doi: 10.1002/acn3.50833 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Arnulf I, Leu-Semenescu S. Sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15;Suppl 3: S101–S104. doi: 10.1016/S1353-8020(09)70792-8 . [DOI] [PubMed] [Google Scholar]
  • 37.Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8: 171–181. doi: 10.1038/nrn2092 . [DOI] [PubMed] [Google Scholar]
  • 38.Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s disease. Parkinsonism Relat Disord. 2010;16: 79–84. doi: 10.1016/j.parkreldis.2009.08.007 . [DOI] [PubMed] [Google Scholar]
  • 39.Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol. 2003;184: 1010–1016. doi: 10.1016/S0014-4886(03)00388-1 . [DOI] [PubMed] [Google Scholar]
  • 40.Ang BT, Tan WL, Lim J, Ng I. Cerebrospinal fluid orexin in aneurysmal subarachnoid haemorrhage—a pilot study. J Clin Neurosci. 2005;12: 758–762. doi: 10.1016/j.jocn.2004.09.021 . [DOI] [PubMed] [Google Scholar]
  • 41.Munts AG, Zijlstra FJ, Nibbering PH, Daha MR, Marinus J, Dahan A, et al. Analysis of cerebrospinal fluid inflammatory mediators in chronic complex regional pain syndrome related dystonia. Clin J Pain. 2008;24: 30–34. doi: 10.1097/AJP.0b013e318156d961 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Claudio Liguori

21 Nov 2022

PONE-D-22-21585Decreased  cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective studyPLOS ONE

Dear Dr. Ogawa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

 Please review the manusript giving more informations about novelty and clinical significance of the results proposed.

Please submit your revised manuscript by Jan 05 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Claudio Liguori

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Additional Editor Comments (if provided):

The Authors proposed an interesting study about CSF orexin levels in patients with PD. Several studies already proposed the same topic and Authors should better delineate the novelty of their research. The main criticism is the lack of pathological reduction of CSF orexin levels in patients than controls, although CSF orexin levels at the mere statistical analysis resulted lower. Authors should better discuss their results.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Understanding the role of orexin in Parkinson’s disease (PD) is an intriguing challenge, with both physiopathological and therapeutic implications.

In this retrospective study Authors tried to investigate a possible alteration of orexin levels in PD. Authors also looked for possible correlations between altered orexin levels and sleep disorders / clinical characteristics of the pathology.

I appreciated Authors’ purpose and study design. The introduction of the study rightly takes into account several controversial findings.

Clear rationale, appropriate methods and analysis, well-argued introduction and discussion.

The major finding of this study, according to several previous reports, is that PD patients showed decreased CSF orexin levels. However, orexin levels showed no correlation with any clinical characteristic, that is, neither with sleep disorders nor with disease gravity/progression.

I greatly appreciate the large number of CSF samples of PD patients, that in my opinion is a great strength of this study.

The same authors well explained the limitations of the study, which do not interfere with the scientific validity of the study.

Moreover, it is a well written article.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Rocco Cerroni

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Dec 30;17(12):e0279747. doi: 10.1371/journal.pone.0279747.r002

Author response to Decision Letter 0

12 Dec 2022

Response to Reviewer and Editor

#1 Journal Requirements

We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Answer to #1

Thank you for the notion. Our data is now available in the Dryad repository (https://datadryad.org/stash/share/IFCMVjwCZFzhhIQncweMKlKNH0pP4Fs1h3khfr0VAD0), as we described in the online submission system. The dataset will be available in the citation below after publication.

(Ogawa, Takuya et al. (2022), dataset_of_CSF_orexin_level_in_PD_with_clinical_assessment, Dryad, Dataset, https://doi.org/10.5061/dryad.905qfttq0)

#2 Additional Editor Comments

The Authors proposed an interesting study about CSF orexin levels in patients with PD. Several studies already proposed the same topic and Authors should better delineate the novelty of their research. The main criticism is the lack of pathological reduction of CSF orexin levels in patients than controls, although CSF orexin levels at the mere statistical analysis resulted lower. Authors should better discuss their results.

Answer to #2

We agree with your point regarding the lack of pathological reduction of CSF orexin levels in patients compared to controls, although CSF orexin levels were statistically lower. We already mentioned the novelty in terms of the large sample and various sufficient clinical evaluations. We also added a new sentence to the introduction section (p. 6 Lines 105-107) to clarify our motivation for this study. We also reconstructed the discussion section to describe the minimal pathological meaning of a decreased CSF orexin level in PD compared to controls (p. 18, Lines 350-351; p. 18, Lines 355-357; p. 20 Lines 398-400).

(Section 1. Introduction) Page 6, lines 105-107:

“Since previous studies had insufficient samples or used inconsistent methods of clinical assessment [10,11,13,14,16,18,19,21], the diagnostic or prognostic value of the CSF orexin level in PD lacks evidence. In this study, we measured orexin levels in the CSF samples obtained from patients with PD to clarify the role of orexin as a biomarker of PD, in the following particulars:...”

(Section 2. Discussion > Orexin in PD compared to controls) Page 18, lines 348

“Our study showed that CSF orexin levels in patients with PD were lower than those in the controls. However, the pathological relevance of CSF orexin levels needs to be considered. The normal range for CSF orexin level defined for the diagnosis of narcolepsy is as follows: over 200 pg/mL is normal, between 110 and 200 pg/mL is intermediate, and under 110 pg/mL is abnormal [34].”

Page 18, lines 354-356

“Although one study showed that CSF orexin levels in patients with PD decreased to an intermediate range [13], other studies demonstrated normal CSF orexin levels in these patients [11,12].”

(Section 3. Discussion > Correlation of orexin with clinical characteristics) Page 20, lines 395-397

“Our study showed no significant differences in CSF orexin levels between patients with PD with and those without DAs. Since our study was retrospective, it is possible that DA had already been discontinued owing to adverse effects. A previous study showed an improvement in EDS and an increase in CSF orexin levels after switching from PPX to pergolide [14]. In clinical situations, the effect of DA use on orexin levels seems to be small, but further studies are needed to focus on cases with adverse sleep events.

Taking all the results together, we believe that the decreased orexin level in patients with PD does not exert a substantial effect on the PD pathologies, at least at the relatively early stage that we have examined.“

Attachment

Submitted filename: 20221211rebuttalletter.docx

Click here for additional data file. (20.2KB, docx)

Decision Letter 1

Claudio Liguori

15 Dec 2022

Decreased  cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study

PONE-D-22-21585R1

Dear Dr. Ogawa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Claudio Liguori

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Claudio Liguori

21 Dec 2022

PONE-D-22-21585R1

Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study

Dear Dr. Ikenaka:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Claudio Liguori

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Correlation between cerebrospinal fluid orexin levels and clinical characteristics in Parkinson’s disease.

    The table shows Spearman’s rank correlation coefficients for orexin levels and clinical characteristics. No clinical characteristics showed a significant correlation with CSF orexin levels. 95%CI, 95% confidence interval; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HYscale, Hoehn and Yahr scale; MDS-UPDRS(I)—(IV), Movement Disorder Society—Unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale.

    (XLSX)

    Click here for additional data file. (9.7KB, xlsx)
    S2 Table. Correlation between longitudinal changes orexin levels and clinical characteristics in Parkinson’s disease.

    The table shows the Spearman’s rank correlation coefficients for longitudinal changes in orexin levels and clinical characteristics. There were no significant correlations between longitudinal changes in orexin levels and clinical characteristics. 95%CI, 95% confidence interval; Δ-, increment of -; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HYscale, Hoehn and Yahr scale; MDS-UPDRS(I)—(IV), Movement Disorder Society—unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale.

    (XLSX)

    Click here for additional data file. (9.8KB, xlsx)
    S3 Table. Correlation between initial cerebrospinal fluid orexin levels and longitudinal changes in clinical characteristics in Parkinson’s disease.

    The table shows Spearman’s rank correlation coefficients for initial orexin levels and longitudinal changes in clinical characteristics. There was no significant correlation between initial CSF orexin levels and longitudinal changes in clinical characteristics. 95%CI, 95% confidence interval; Δ-, increment of -; ESS, Epworth Sleepiness Scale; RBDQ, Rapid Eye Movement Sleep Behavior Disorder Questionnaire; HYscale, Hoehn and Yahr scale; MDS-UPDRS(I)—(IV), Movement Disorder Society—unified Parkinson’s Disease Rating Scale part 1 to 4; PDQ-39, Parkinson’s Disease Questionnaire; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery; Olfactory, Olfactory identification score; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; GDS-15, Geriatric Depression Scale; AS, Apathy Scale.

    (XLSX)

    Click here for additional data file. (10.7KB, xlsx)
    Attachment

    Submitted filename: 20221211rebuttalletter.docx

    Click here for additional data file. (20.2KB, docx)

    Data Availability Statement

    All data files are available from the Dryad database (DOI: 10.5061/dryad.905qfttq0).

    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES